Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Outlook Therapeutics, Inc.

Clinical trials sponsored by Outlook Therapeutics, Inc., explained in plain language.

Outlook Therapeutics, Inc. OTLK NASDAQ

Biopharmaceutical company developing ophthalmic therapies.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Not yet finished but already full! 1 Completed 3

New syringe design tested for common eye disease treatment

Disease control Ongoing

This study tests whether a pre-filled syringe is as safe as the traditional vial when giving the medicine bevacizumab for certain eye diseases. About 120 people with wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion will receive inject…

Phase: PHASE3 • Sponsor: Outlook Therapeutics, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:23 UTC